PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Bone cancer; Brain metastases; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Gastric cancer; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Glioblastoma; Glioma; Haematological malignancies; Head and neck cancer; Hodgkin's disease; Human papillomavirus infections; Inflammatory breast cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Multiple myeloma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Penile cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thymoma; Thyroid cancer; Urogenital cancer
- Focus Adverse reactions; Proof of concept
- 31 Aug 2018 Biomarkers information updated
- 11 Aug 2018 Planned number of patients changed from 17 to 20.
- 04 Apr 2018 Planned initiation date changed from 3 Apr 2018 to 10 Apr 2018.